Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors

Journal of Toxicological Sciences

Volumn 24, Issue 1, 1999, Pages 1-16

  Kobayashi, Haruo ^a   Suzuki, Tadahiko ^a   Kamata, Ryo ^a   Saito, Shin Ya ^b   Sato, Itaru ^a   Tsuda, Shuji ^a   Matsusaka, Naonori ^a  

^a IWATE UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Anandamide; Dependence; Endomorphin; Morphine; Nicotine; Tetrahydrocannabinol

Indexed keywords

ANANDAMIDE; BRAIN RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; CHOLINERGIC RECEPTOR; ENDORPHIN; MORPHINE; NEUROTOXIN; NICOTINE; NICOTINIC RECEPTOR; OPIATE; TETRAHYDROCANNABINOL;

AGONIST; CENTRAL NERVOUS SYSTEM; DRUG DEPENDENCE; HUMAN; MAMMAL; NEUROTOXICOLOGY; NONHUMAN; RECEPTOR BINDING; REVIEW; TOBACCO;

CANNABIS; CANNABIS SATIVA; MAMMALIA; NICOTIANA TABACUM;

EID: 0032978948     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.24.1     Document Type: Review

References (96)

1. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. and Tao, Q.(1997): Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem. Pharmacol., 53, 207-214.
2. Adams, I. B., Compton, D. R. and Martin, B. R. (1998): Assessment of anandamidc interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Therap., 284: 1209-1217.
3. Albuquerque, E. X., Alkondon, M., Pereira, E. F. R., Castro, N. G., Schrattenholz, A., Barbosa, C. T. F., Bonfante-Cabarcas, R., Aracava, Y., Eisenberg, H. M. and Maelicke, A. (1997): Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Therap., 280, 1117-1136.
4. Anand, R., Conroy, W. G., Schoepfer, R., Whiting, P. and Lindstrom, J. (1991): Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J. Biol. Chem., 266, 11192-11198.
5. Balfour, D. J. (1996): Neural mechanisms underlying nicotinic dependence. Addiction, 89, 1419-1423.
6. Benowitz, N. L. (1992): Cigarette smoking and nicotine addiction. Med. Clin. North Am. 76, 415-437.
7. 3H]nicotine binding sites in human brain. J. Neurochem., 50, 1243-1247.
8. Besse, D., Lombard, M. C., Zajac, J. M., Roques, B. P. and Besson, J. M. (1990): Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res., 521, 15-22.
9. Block, R. I., Farinpour, R. and Braverman, K. (1992): Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacol. Biochem. Behav. 43, 907-917.
10. Block, R. I. and Ghoneim, M. M. (1993): Effects of chronic marijuana use on human cognition. Psychopharmacology, 110, 219-228.
11. 3H]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Therap., 282, 7-13.
12. Breivogel, C. S., Sim, L. J. and Childers, S. R. (1997): Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Therap., 282, 1632-1642.
13. Busquests, X., Escriba, P. V., Sastre, M. and Garcia-Sevilla, J. (1995): Loss of protein kinase C- α β in brain of heroin addicts and morphine-dependent rats. J. Neurochem., 64, 247-252.
14. Chaillet, P., Coulaud, A., Zajac, J. M., Fournie-Zaluski, M. C., Costentin, J. and Roques, B. P. (1984): The mu rather than the delta subtype of opioid receptors appears to be involved in enkephalin-induced analgesia. Eur. J. Pharmacol., 101, 83-90.
15. Chakrabarti, A., Onaivi, E. S. and Chaudhuri, G. (1995): Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA-Seq., 5, 385-388.
16. Childers, S. R. (1991) Opioid receptor-coupled second messenger systems. Life Sci., 48, 1991-2003.
17. Collin, E. and Cesselin, F. (1991): Neurobiological mechanisms of opioid tolerance and dependence. Clin. Pharmacol., 14, 465-488.
18. Colpaert, F. C. (1995): Drug discrimination. No evidence for tolerance to opiates. Pharmacol. Rev., 47, 605-629.
19. Colpaert, F. C., Niemegeers, C. J. E. and Janssen, P. A. J. (1978): Studies on regulation of sensitivity to the narcotic cue. Neuropharmacology, 17, 705-713.
20. Compton, D. R. and Martin, B. R. (1997): The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Therap., 283, 1138-1143.
21. Cooper, J. R., Bloom, F. B. and Robert, H. R. (1996): Acetylcholine. In The Biochemical Basis of Neuropharmacology., 7th ed., 194-225, Oxford University Press, Oxford.
22. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A. and Axelrod, J.(1993): Anandamide, an endogenous iigand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav., 46, 967-972.
23. Creese, I. and Sibley, D. R. (1981): Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol., 21, 357-391.
24. Dani, J. A. and Heinemann, S. (1996): Molecular and cellular aspects of nicotine abuse. Neuron, 16, 905-908.
25. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
26. Deway, W. L. (1986): Cannabinoid pharmacology. Pharmacol. Rev., 38, 151-178.
27. Dhawan, B. N., Cesselin, F., Raghubir, R., Reisine, T., Bradley, P. B., Portoghese, P. S. and Hamon, M. (1996): International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev., 48, 567-592.
28. Dhawan, B. N., Raghubir, R. and Hamon, M. (1998): Opioid receptors. In The IUPHAR Compendium of Receptor Characterization and Classification (Godfraind, T., Vanhoutte, P. M., Ruffolo, R. R. and Humphrey, P. P. A. eds.)., 1st ed., 218-226, IUPHAR Media, London.
29. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C. and Piomelli, D. (1994): Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (Lond.), 372, 686-691.
30. 2]deltorphin- I: a high affinity, delta-selective opioid receptor ligand. Peptides, 12, 825-830.
31. Emmerson, P. J., Liu, M. R., Moods, J. H. and Medzihradsky, F. (1994): Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Therap., 271, 1630-1637.
32. Emmett-Oglesby, M. W., Shippenberg, T. S. and Herz, A. (1988): Fentanyl and morphine discrimination in rats continuously infused with fentanyl. Behav. Pharmacol., 1, 3-11.
33. Fang, F. G., Fields, H. L. and Lee, N. M. (1986): Action at the mu receptor is sufficient to explain the supraspinal analgesic effect of opiates. J. Pharmacol. Exp. Therap., 238, 1039-1044.
34. Felder, C. C. and Glass, M. (1998): Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol., 38: 179-200.
35. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L. and Mitchell, R. L. (1995): Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48: 443-450.
36. Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B. and Kellar, K. J. (1992): A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol., 41, 31-37.
37. Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M. C., Reimherr, F., Wender, P., Yaw, J., Young, D. A., Breese, C. R., Adams, C., Patterson, D., Adler, L. E., Kruglyak, L., Leonard, S. and Byerley, W. (1997): Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA, 94, 587-92.
38. Fride, E. and Mechoulam, R. (1993): Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur. J. Pharmacol. 231, 313-314.
39. Gabilondo, A. M., Meana, J. J., Barturen, F., Sastre, M. and Garcia-Sevilla (1994): μ -Opioid receptor and α2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology, 115, 135-140.
40. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le, F. G. and Casellas, P. (1995): Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 54-61.
41. Gatley, S. J., Lan, R., Volkow, N. D., Pappas, N., King, P., Wong, C. T., Gifford, A. N., Pyatt, B., Dewey, S. L. and Makriyannis, A. (1998): Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J. Neurochem., 70, 417-423.
42. Gerard, C. M., Mollereau, C., Vassart, G. and Parmentier, M. (1991): Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279 (Pt 1): 129-134.
43. Gessa, G. L., Mascia, M. S., Casu, M. A. and Carta, G. (1997): Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur. J. Pharmacol., 327, R1-R2.
44. Gifford, A. N. and Ashby, C. R. (1996): Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Therap., 277, 1431-1436.
45. Gray, R., Rajan, A. S., Radcliffe, K. A., Yakehiro, M. and Dani, J. A. (1996): Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature (Lond.), 383, 713-716.
46. Hanus, L., Gopher, A., Almog, S. and Mechoulam, R. (1993): Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem., 36, 3032-3036.
47. Henningfield, J. E., Miyasato, K. and Janinski, D. R. (1983): Cigarette smokers self-administer intravenous nicotine. Pharmacol. Biochem. Behav., 19, 887-890.
48. Henningfield, J. E., Stapleton, J. M., Benowitz, N. L., Grayson, R. F. and London, E. D. (1993): Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend., 33, 23-29.
49. Higgins, G. A. and Sellers, E. M. (1994): Antagonist-precipitated opioid withdrawal in rats: Evidence for dissociations between physical and motivational signs. Pharmacol. Biochem. Behav., 48, 1-8.
50. Hirschhorn, I. D. and Rosecrans, J. A. (1974): Morphine and delta-9-tetrahydrocannabinol: tolerance to the stimulation effects. Psychopharmacology 36, 243-253.
51. Holsapple, M. P., Karras, J. G., Ledbetter, J. A., Schieven, G. L., Burchiel, S. W., Davila, D. R., Schatz, A. R. and Kaminski, N. E. (1996): Molecular mechanisms of toxicant-induced immunosuppression: Role of second messengers. Annu. Rev. Pharmacol. Toxicol., 35, 131-159.
52. Howlett, A. C. (1995): Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol., 35, 607-634.
53. Hunter, J. C., Leighton, G. E., Meecham, K. G., Boyle, S. J., Horwell, D. C., Rees, D. C. and Hughes, J. (1990): CI-977, a novel and selective agonist for the kappa-opioid receptor. Brit. J. Pharmacol., 101, 183-189.
54. Kumor, K. M. and O'Brien, C. P. (1994): Substance abuse. In Biological Bases of Brain Function and Disease (Frazer, A., Molinoff, P. B. and Winokur, A. , eds.) , pp. 357-384, Raven Press, New York.
55. Lazarus, L. H., Bryant, S. D., Salvadori, S., Attila, M. and Jones, L. S. (1996): Opioid infidelity: novel opioid peptides with dual high affinity for d- and m-receptors. Trends Neurosci., 19, 31-35.
56. Lefkowitz, R. J., Hoffman, B. B. and Taylor, P. (1996): Neurotransmission. The autonomic and somatic motor nervous systems. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman, J. G., Lombird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. eds), 9th ed., pp. 105-139, McGraw-Hill, New York.
57. Lord, J. A. H., Waterfield, A. A., Hughes, J. and Kosterlitz, H. W. (1977): Endogenous opioid peptides: multiple agonists and receptors. Nature (Lond.) 267, 495-499.
58. Mansour, A., Fox, C. A., Burke, S., Meng, F., Thompson, R. C., Akil, H. and Watson, S. J. (1994): Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. Comp. Neurol., 350, 412-438.
59. Marks, M. J., Grady, S. R. and Collins, A. C. (1993): Downregulation of nicotine receptor function after chronic nicotine infusion. J. Pharmacol. Exp. Therap., 266, 1268-1276.
60. McGehee, D. S. and Role, L. W. (1995): Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol., 57, 521-546.
61. Munro, S., Thomas, K. L. and Abu, S. M. (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond.), 365, 61-65.
62. Noble, F. and Cox, B. M. (1997): The role of dopaminergic systems in opioid receptor desensitization in nucleus accumbens and caudate putamen of rat after chronic morphine treatment. J. Pharmacol. Exp. Therap., 283, 557-565.
63. Nock, B., Giordano, A. L. and Cicero, T. J. (1989): ICI 197067 is a selective ligand for the U-69593-sensitive kappa opiate binding site. Eur. J. Pharmacol., 162, 385-386.
64. O'Brien, C. P. (1996): Drug addiction and drug abuse. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman, J. G., Lombird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. eds), 9th ed., pp. 557-577, McGraw-Hill, New York.
65. Olale, F., Gerzanich, V., Alexander, K., Wang, F. and Lindstrom, J. (1997): Chronic exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J. Pharmacol. Exp. Therap., 283, 675-683.
66. Ozaita, A., Escriba, P. V., Murga, C., Mayor, F. and Garcia-Sevilla, J. A. (1998): Regulation of G protein-coupled receptor kinase 2 in brains of opiatetreated rats and human opiate addicts. J. Neurochem., 70, 1249-1257.
67. Paul, D., Bodnar, R. J., Gistrak, M. A. and Pasternak, G. W. (1989): Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmacol., 168, 307-314.
68. Pierce, T. L., Grahek, M. D. and Wessendorf, M. W. (1998): Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport, 9, 385-389.
69. Porreca, F., Mosberg, H. I., Hurst, R., Hruby, V. J. and Burks, T. F. (1984): Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J. Pharmacol. Exp. Therap., 230, 341-348.
70. Porreca, F., Mosberg, H. I., Omnaas, J. R., Burks, T. F. and Cowan, A. (1987): Supraspinal and spinal potency of selective opioid agonists in the mouse writhing test. J. Pharmacol. Exp. Therap., 240, 890-894.
71. Reisine, T. and Pasternak, G. (1996): Opioid analgesics and antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman, J. G., Lombird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. eds), 9th ed., pp. 521-554, McGraw-Hill, New York.
72. Renda, T., Negri, L., Tooyama, I., Casu, C. and Melchiorri, P. (1993): Autoradiographic study on [3H]-[D-Ala2]-deltorphin-I binding sites in the rat brain. Neurorcport, 4, 1143-1146.
73. Rogers, N. F. and El-Fakahany, E. E. (1986): Morphine-induced opioid receptor down-regulation detected in intact adult rat brain cells. Eur. J. Pharmacol., 124, 221-230.
74. Ross, E. M. (1996): Pharmacodynamics. Mechanisms of drug action and the relatioship between drug concentration and effect. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman, J. G., Lombird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. eds), 9th ed., pp. 29-41, McGraw-Hill, New York.
75. Sannerud, C. A. and Young, A. M. (1987): Environmental modification of tolerance to morphine discriminative stimulus properties in rats. Psychopharmacology, 93, 59-68.
76. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. and Kaminski, N. E. (1997): Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142, 278-287.
77. Shannon, H. E. and Holtzman, S. G. (1976): Evaluation of discriminative effects of morphine in the rat. J. Pharmacol. Exp. Therap., 198, 54-65.
78. Shen, M., Piser, T. M., Seybold, V. S. and Thayer, S. A. (1997): Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci., 16, 4322-4334.
79. Schlicker, E., Timm, J., Zentner, J. and Göthert, M. (1997): Cannabinoid receptor-mediated inhibition of noradrenaline release in the human and guineapig hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 583-589.
80. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R. and Martin, B. R. (1994): The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Therap., 270, 219-227.
81. Solowij, N., Michie, P. T. and Fox, A. M. (1995): Differential impairments of selective attention due to frequency and duration of cannabis use. Biol. Psichiatry, 37, 731-739.
82. Stella, N., Schweizer, P. and Piomelli, D. (1997): A second endogenous cannabinoid that modulates long-term potentiation. Nature (Lond.), 388, 773-778.
83. Stone, L. S., Fairbanks, C. A., Laughlin, T. M., Nguyen, H. O., Bushy, T. M., Wessendorf, M. W. and Wilcox-GL (1997): Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport, 8, 3131-3135.
84. Taylor, P. (1996): Agents acting at the neuromuscular junction and autonomic ganglia. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman, J. G., Lombird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. eds), 9th ed., pp. 177-197, McGraw-Hill, New York.
85. Tempel, A. and Zukin, R. S. (1987): Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc. Natl. Acad. Sci. USA, 84, 4308-4312.
86. Unwin, N. (1995): Acetylcholine receptor channel imaged in the open state. Nature (Lond.), 373, 37-43.
87. Wada, E., Wada, K., Boulter, J., Deneris, E., Heinemann, S., Patrick, J. and Swanson, L. W. (1989): Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol., 284, 314-335.
88. Waksman, G., Hamel, E., Fournie-Zaluski, M. C. and Roques, B. P. (1986): Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain. Proc. Natl. Acad. Sci. USA, 83, 1523-1527.
89. Werling, L. L., McMahon, P. N. and Cox, B. M. (1989): Selective changes in μ opioid receptor properties induced by chronic morphine exposure. Proc. Natl. Acad. Sci. USA, 86, 6393-6397.
90. 9-tetrahydrocamiabinol fails to irreversibly alter brain cannabinoid receptors. Brain Res., 544, 145-149.
91. Whiting, P. and Lindstrom, J. (1987): Purification and characterization of a nicotinic acetylcholine receptor from rat brain. Proc. Natl. Acad. Sci. USA, 84, 595-599.
92. Willoughby, K. A., Moore, S. F., Martin, B. R. and Ellis, E. F. (1997): The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Therap., 282, 243-247.
93. Witschi, H., Joad, J. P. and Pinkerton, K. E. (1997): The toxicology of environmental tobacco smoke. Annu. Rev. Pharmacol. Toxicol., 37, 29-52.
94. Wonnacott, S. (1990): The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci., 11, 216-219.
95. Zadina, J. E., Hackler, L., Ge, L.-J. and Kastin, A. J. (1997a): A potent and selective endogenous agonist for the μ -opiate receptor. Nature (Lond.), 386, 499-502.
96. Zadina, J. E., Hackler, L., Ge, L.-J. and Kastin, A. J. (1997b) : Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides, 18, 1635-1639.